期刊论文详细信息
BMC Cancer
KAI1 suppresses HIF-1α and VEGF expression by blocking CDCP1-enhanced Src activation in prostate cancer
Research Article
Young-Gyu Ko1  Yun-Sil Lee2  Yeung Bae Jin3  Yoon-Jin Lee3  Minyoung Lee3  Jung-Jin Park4  Jae-Seon Lee5 
[1] College of Life Sciences and Biotechnology, Korea University, 1, 5-ka, Anam-dong, 136-701, Sungbuk-gu, Seoul, Republic of Korea;College of Pharmacy & Division of Life & Pharmaceutical Sciences, Ewha Womans University, 11-1 Daehyun-Dong, 120-750, Seodaemun-Gu, Seoul, South Korea;Division of Radiation Effect, Korea Institute of Radiological and Medical Sciences, 139-706, Nowon-Ku, Seoul, South Korea;Division of Radiation Effect, Korea Institute of Radiological and Medical Sciences, 139-706, Nowon-Ku, Seoul, South Korea;College of Life Sciences and Biotechnology, Korea University, 1, 5-ka, Anam-dong, 136-701, Sungbuk-gu, Seoul, Republic of Korea;Division of Radiation cancer Research, Korea Institute of Radiological and Medical Sciences, 139-706, Nowon-Ku, Seoul, South Korea;
关键词: Vascular Endothelial Growth Factor;    Vascular Endothelial Growth Factor Expression;    Tetraspanin Protein;    KAI1 Expression;    Vascular Endothelial Growth Factor Promoter Activity;   
DOI  :  10.1186/1471-2407-12-81
 received in 2011-07-26, accepted in 2012-03-06,  发布年份 2012
来源: Springer
PDF
【 摘 要 】

BackgroundKAI1 was initially identified as a metastasis-suppressor gene in prostate cancer. It is a member of the tetraspan transmembrane superfamily (TM4SF) of membrane glycoproteins. As part of a tetraspanin-enriched microdomain (TEM), KAI1 inhibits tumor metastasis by negative regulation of Src. However, the underlying regulatory mechanism has not yet been fully elucidated. CUB-domain-containing protein 1 (CDCP1), which was previously known as tetraspanin-interacting protein in TEM, promoted metastasis via enhancement of Src activity. To better understand how KAI1 is involved in the negative regulation of Src, we here examined the function of KAI1 in CDCP1-mediated Src kinase activation and the consequences of this process, focusing on HIF-1 α and VEGF expression.MethodsWe used the human prostate cancer cell line PC3 which was devoid of KAI1 expression. Vector-transfected cells (PC3-GFP clone #8) and KAI1-expressing PC3 clones (PC3-KAI1 clone #5 and #6) were picked after stable transfection with KAI1 cDNA and selection in 800 μg/ml G418. Protein levels were assessed by immunoblotting and VEGF reporter gene activity was measured by assaying luciferase activitiy. We followed tumor growth in vivo and immunohistochemistry was performed for detection of HIF-1, CDCP1, and VHL protein level.ResultsWe demonstrated that Hypoxia-inducible factor 1α (HIF-1α) and VEGF expression were significantly inhibited by restoration of KAI1 in PC3 cells. In response to KAI1 expression, CDCP1-enhanced Src activation was down-regulated and the level of von Hippel-Lindau (VHL) protein was significantly increased. In an in vivo xenograft model, KAI1 inhibited the expression of CDCP1 and HIF-1α.ConclusionsThese novel observations may indicate that KAI1 exerts profound metastasis-suppressor activity in the tumor malignancy process via inhibition of CDCP1-mediated Src activation, followed by VHL-induced HIF-1α degradation and, ultimately, decreased VEGF expression.

【 授权许可】

Unknown   
© Park et al; licensee BioMed Central Ltd. 2012. This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

【 预 览 】
附件列表
Files Size Format View
RO202311095366696ZK.pdf 3765KB PDF download
【 参考文献 】
  • [1]
  • [2]
  • [3]
  • [4]
  • [5]
  • [6]
  • [7]
  • [8]
  • [9]
  • [10]
  • [11]
  • [12]
  • [13]
  • [14]
  • [15]
  • [16]
  • [17]
  • [18]
  • [19]
  • [20]
  • [21]
  • [22]
  • [23]
  • [24]
  • [25]
  • [26]
  • [27]
  • [28]
  • [29]
  • [30]
  • [31]
  • [32]
  • [33]
  • [34]
  • [35]
  • [36]
  • [37]
  • [38]
  • [39]
  • [40]
  • [41]
  • [42]
  • [43]
  • [44]
  • [45]
  • [46]
  • [47]
  • [48]
  文献评价指标  
  下载次数:1次 浏览次数:0次